FDA approves Novartis Scemblix® (asciminib), with novel mechanism of action for the treatment of chronic myeloid leukemia

NEXT STORY
Pfizer and BioNTech Receive First U.S. FDA Emergency Use Authorization of a COVID-19 Vaccine in Children Ages 5 Through 11 Years
PREV STORY
BioAegis Therapeutics to Present “Conquering Pneumonia and Systemic Inflammation with a Human Protein,” at the MACRO Trends Investor Conference in Belgium
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Daxor’s BVA-100® Published in Novel Study in American Heart Association Journal – Circulation

author_avatar
NASDAQ Market News

Data Published In AACR Journal Suggest Biodesix® Test in Development May Identify Melanoma Patients Who Could Benefit from Checkpoint Inhibitors

BOULDER, Colo., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Findings published in the American Association ...

author_avatar
NASDAQ Market News

Women’s Choice Award® Announces Best Children’s Hospitals for 2018

author_avatar
NASDAQ Market News